AI Article Synopsis
- Angiogenesis, the formation of new blood vessels, is an early step in the process of tumor development.
- Researchers are currently conducting clinical trials on new drugs that inhibit angiogenesis to combat cancer growth.
- Thalidomide has gained renewed interest as it helps block angiogenesis, proving effective as a palliative treatment for blood cancers like multiple myeloma and myelodysplastic syndromes.
Article Abstract
The angiogenesis is an early event in tumorigenesis. Angiogenesis inhibitors have been developed and are now studied in clinical trials. Angiogenesis research has induced a renewal of thalidomide. Thalidomide inhibits tumoral angiogenesis, allowing a good palliative treatment for hematological malignancies, especially for multiple myeloma and myelodysplastic syndromes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physcian's perspective.
J Pharm Policy Pract
July 2020
Department of Gastroenterology and Hepatology, Amsterdam UMC, VU University Medical Center, AG&M Research Institute, Amsterdam, The Netherlands.
Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indications to existing drugs for lower costs compared to de novo drug development. Clinical research groups recognizing efficacy of these "old" drugs for a new indications often face an uphill struggle due to a lack of funding and support because of poor structural and regulatory support for clinical drug development.
View Article and Find Full Text PDF[Thalidomide: (re)discovery of a not very dear old molecule].
Rev Med Suisse Romande
April 2003
Service d'Oncologie Hôpital des Cadolles, 2000 Neuchâtel.
Article Synopsis
- Angiogenesis, the formation of new blood vessels, is an early step in the process of tumor development.
- Researchers are currently conducting clinical trials on new drugs that inhibit angiogenesis to combat cancer growth.
- Thalidomide has gained renewed interest as it helps block angiogenesis, proving effective as a palliative treatment for blood cancers like multiple myeloma and myelodysplastic syndromes.
Thalidomide, an oral drug introduced in Germany in 1953 as a mild sedative, was withdrawn from the world market when its teratogenic effect was discovered some years later. It has since been selectively reintroduced to treat a variety of autoimmune or inflammatory diseases such as erythema nodosum leprosum, prurigo nodularis, graft-versus-host disease, and discoid lupus erythematosus (DLE). We report on three patients with long-standing, severe DLE showing no response to systemic first-, second- and third-line treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!